{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:43:16Z","timestamp":1788554596634,"version":"build-2803163510"},"reference-count":35,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Diagnostics"],"abstract":"<jats:p>While high-dose therapy and autologous stem cell transplant (ASCT) remain integral to the primary treatment of newly diagnosed transplant-elble multiple myeloma (MM) patients, the challenge of disease progression persists. The primary objective of this meta-analysis is to evaluate the efficacy and safety of tandem ASCT compared to single ASCT. We conducted a systematic review and meta-analysis of randomized controlled trials and observational studies comparing tandem ASCT with single ASCT in patients with newly diagnosed MM. We searched PubMed, EMBASE, Cochrane Library, and Clinical Trials databases for studies published up to January 2024. The primary outcomes were progression-free survival (PFS), overall survival (OS), overall response rate (ORR), complete response rate (CRR), and treatment-related mortality (TRM). We used a random-effects model to calculate pooled hazard ratios (HRs) and relative risks (RRs) with 95% confidence intervals (CIs). Study quality was assessed using the Cochrane risk of bias tool and Newcastle\u2013Ottawa Scale. Twelve studies involving 5057 patients met the inclusion criteria. Tandem ASCT was associated with a significantly higher CRR compared to single ASCT (HR 1.33, 95% CI 1.03\u20131.71, I2 = 15%), but no significant differences were observed in PFS (HR 0.75, 95% CI 0.42\u20131.34, I2 = 14%), OS (HR 0.60, 95% CI 0.33\u20131.10, I2 = 27%), or the ORR (RR 0.80, 95% CI 0.59\u20131.08, I2 = 33%). However, tandem ASCT was associated with a significantly higher risk of TRM (RR 1.78, 95% CI 1.00\u20133.18, I2 = 0%). Tandem ASCT improves the CRR but does not provide significant benefits in terms of PFS, OS, or ORR compared to single ASCT in patients with newly diagnosed MM. Moreover, tandem ASCT is associated with a higher risk of TRM. The decision to pursue tandem ASCT should be made on an individual basis, carefully weighing the potential benefits and risks in light of each patient\u2019s unique clinical situation. Future research should focus on identifying patient subgroups most likely to benefit from tandem ASCT and exploring strategies to optimize the efficacy and safety of this approach in the context of novel agent-based therapies.<\/jats:p>","DOI":"10.3390\/diagnostics14101030","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T06:44:31Z","timestamp":1715841871000},"page":"1030","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Efficacy and Safety of Tandem Transplant Versus Single Stem Cell Transplant for Multiple Myeloma Patients: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-7439","authenticated-orcid":false,"given":"Yu-Han","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Englewood Hospital and Medical Center, Englewood, NJ 07631, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3678-2805","authenticated-orcid":false,"given":"Lindsay","family":"Fogel","sequence":"additional","affiliation":[{"name":"Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2242-0447","authenticated-orcid":false,"given":"Chieh","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, University of California Riverside, Riverside, CA 92521, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4854-7414","authenticated-orcid":false,"given":"Rushin","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Community Hospital of San Bernardino, San Bernardino, CA 92411, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8937-6105","authenticated-orcid":false,"given":"Wei-Cheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan 330, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-6417","authenticated-orcid":false,"given":"Po-Huang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3304-4643","authenticated-orcid":false,"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Changhua Christian Hospital, Changhua 500, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeu-Chin","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-5243","authenticated-orcid":false,"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-5168","authenticated-orcid":false,"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"ref_1","unstructured":"(2024, May 12). National Comprehensive Cancer Network Multiple Myeloma, Version 1. Available online: https:\/\/www.nccn.org\/guidelines\/category_1."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Bazarbachi","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: Recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.bbmt.2019.07.004","article-title":"Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"Gagelmann","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/bjh.13994","article-title":"Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: Long-term results from the phase III GMMG-HD2 trial","volume":"173","author":"Mai","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V128.22.991.991","article-title":"Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02\/HO95 MM Trial)","volume":"128","author":"Cavo","year":"2016","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: Diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin. Proc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: A PETHEMA\/GEM trial","volume":"31","author":"Rosinol","year":"2017","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: Long-term follow-up","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040620718761776","article-title":"The evolution of stem-cell transplantation in multiple myeloma","volume":"9","author":"Mahajan","year":"2018","journal-title":"Ther. Adv. Hematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1200\/JCO.2006.10.2509","article-title":"Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study","volume":"25","author":"Cavo","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: A systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_18","first-page":"401","article-title":"Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02\/HO95 Study","volume":"130","author":"Cavo","year":"2017","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/jjco\/hyl041","article-title":"Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma","volume":"36","author":"Eom","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/blood.V114.22.2320.2320","article-title":"Single Versus Tandem High Dose Therapy (HDT) Supported with Autologous Blood Stem Cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC: Long-Term Results of a Two by Two Designed Randomized Trial in 225 Young Patients with Multiple Myeloma (MM). for the Group \u201cMyelome-Autogreffe\u201d, Caen, Creteil, Limoges, Paris, Strasbourg, France","volume":"114","author":"Fermand","year":"2009","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3324\/haematol.11168","article-title":"Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: Long-term follow-up of the Dutch Cooperative Group HOVON 24 trial","volume":"92","author":"Sonneveld","year":"2007","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1515\/med-2021-0216","article-title":"Comparison of single and double autologous stem cell transplantation in multiple myeloma patients","volume":"16","author":"Malkan","year":"2021","journal-title":"Open Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/ejh.13922","article-title":"Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis","volume":"110","author":"Suzuki","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_25","unstructured":"Higgins, J.P. (2011). GS Cochrane Handbook for Systematic Reviews of Interventions, Cochrane Collaboration. Available online: http:\/\/wwwcochrane-handbookorg."},{"key":"ref_26","unstructured":"Wells, G.A., Shea, B., O\u2019Connell, D., Peterson, J., Welch, V., Losos, M., and Tugwell, P. (2023, February 05). The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Available online: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_28","unstructured":"(2024, May 12). Review Manager Web (RevMan Web) Version 4120 The Cochrane Collaboration. Available online: https:\/\/revman.cochrane.org\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus au tograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Sureda","year":"2008","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2269509","DOI":"10.1080\/16078454.2023.2269509","article-title":"Autologous followed by allogeneic versus tandem-autologous transplantation in high-risk, newly diagnosed multiple myeloma: A systematic review and meta-analysis","volume":"28","author":"Wei","year":"2023","journal-title":"Hematology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/hematology.2021000229","article-title":"High-riskmultiple myeloma: How to treat at diagnosis andrelapse?","volume":"2021","author":"Mateos","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: Predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.3390\/diagnostics15232942","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000}}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/10\/1030\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:24:36Z","timestamp":1764325476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/14\/10\/1030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["diagnostics14101030"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics14101030","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}